Form 4: Biocryst Pharmaceuticals Director Acquires Shares

Biocryst Pharmaceuticals Director Amy E. McKee acquired 631 shares of common stock on May 29, 2026, as part of her board member retainer.

Summary

• Amy E. McKee, a Director at Biocryst Pharmaceuticals Inc., acquired 631 shares of common stock on May 29, 2026.
• The acquisition was made in lieu of 50% of her quarterly cash Board Member retainer, valued at $11,250.
• The shares were acquired at a price of $8.91 per share.
• Following this transaction, Ms. McKee beneficially owns 31,883 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine compensation adjustment rather than a significant strategic or financial event.

Positives

• Director's continued investment in the company through share acquisition.
• Alignment of director compensation with equity ownership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider share acquisitions, particularly when tied to compensation, can signal confidence from management and directors in the company's prospects, though this specific transaction is a routine part of director compensation structure.

Stakeholder Impact

• Shareholders: The transaction represents a minor increase in director's equity stake, aligning their interests with shareholders.
• Employees: No direct impact on employees is indicated by this filing.
• Creditors: No impact on creditors is indicated by this filing.

Key Dates

Keywords

Biocryst Pharmaceuticals, BCRX, Form 4, Insider Trading, Share Acquisition, Director Compensation, SEC Filing